A Phase I Study of ASA 404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Patients With Refractory Solid Tumors.
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 09 May 2013
At a glance
- Drugs Vadimezan (Primary) ; Carboplatin; Cetuximab; Paclitaxel
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 23 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 Feb 2011 Actual initiation date changed from Dec 2009 to Jan 2010 as reported by ClinicalTrials.gov.